2024-06-22-accounts - Radiotherapy UK

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Trustees’ Annual Report for the period

	Period start date	Period start date	Period start date			Period end date	Period end date
	Day	Month	Year		Day	Month	Year
From	23	June	2023	To	22	June	2024

Charity name				Radiotherapy UK
Other names charity is known by				ACCORN
				Action Radiotherapy
Charity registration number				1135902

Objectives and Activities

	SORP reference
Summary of the purposes of the charity as set out in its governing document	Para 1.17	1. To promote, support and encourage research into radiotherapy, radiobiology and allied subjects, and the dissemination of the useful results of such research by such actions as: a. Promoting and facilitating multidisciplinary collaboration between researchers and practitioners in radiotherapy and its allied subjects b. Informing patients and the public about practice and research in radiotherapy and its allied subjects, and engaging patients and the public in the development of research projects c. Awarding grants as appropriate 2. To advance and benefit the practice of radiotherapy and its allied subjects to relieve sickness and preserve good health by such actions as: a. Promoting and facilitating multidisciplinary networking and sharing of expertise and best practice b. Promoting and encouraging the study of the science and practice of radiotherapy and its allied subjects c. Promoting and facilitating increased involvement of allied professions d. Facilitating development and dissemination of best practices in radiotherapy and its allied subjects e. Disseminating knowledge concerning all aspects of the science and practice of radiotherapy and its allied subjects f. Promoting and facilitating education and training in the research and practice of radiotherapy and its allied subjects

Summary of the main actvites in relaton to those purposes for the public beneft, in partcular, the actvites, projects or services identfed in the accounts.	Para 1.17 and 1.19	1. Patent informaton resources We work to support patents with cancer through the provision of trusted, accessible and relevant informaton resources before, during and following their radiotherapy treatment. We develop Patent Informaton Forum (PIF) accredited resources that means patents and families can trust that what we produce is evidence-based, understandable, jargon-free, up-to-date and produced to the best possible standard. 2. Advocacy and Campaigning We work in partnership with patents, academics, workforce, industry and parliamentarians to campaign for equality of access to world-class radiotherapy for all patents with cancer in the UK. We raise awareness of how harnessing technologically advanced, cost-efectve radiotherapy could treat more patents, quicker. We are proud to be the charity partner of the Radiotherapy4Life campaign and co-founder of the #CatchUpWithCancer campaign. As Secretariat for the APPG- Radiotherapy we work with the Chair and Ofcers in organising events, meetngs and ensuring all APPG regulatons and requirements are met. Our work also has global reach through our partnership with the Global Coaliton for Radiotherapy as we support other countries advocatng for increased access to radiotherapy services. 3. Workforce engagement and support Our work amplifes the voice of the frontline radiotherapy workforce to raise awareness of the issues faced in the delivery of services. We provide opportunites for the workforce to learn and engage with ideas, innovatons and technologies that can support them in developing patent- centred care and practce. We ofer an actve network of radiotherapy professionals who ofer peer support, educaton and insight. We also promote careers in radiotherapy through job listngs shared daily through our platorms and website. 4.General fundraising/events The charity raises funds from a variety of sources including online giving, community events, corporate partnerships, individual donatons and grants. The charity was very grateful to receive support in this fnancial year from B-Clear, Ergea, Brainlab, Elekta, Varien-Siemens-Healthineers, FlenHealth, Amethyst, AstraZeneca, Price-Jones, Accuray and Broyst Foundaton. 5. Research and Data The charity delivers analysis on publicly available data such as waitng-tmes for cancer treatment and produces evidence- based reports and research to beter understand how radiotherapy services are currently being delivered and what needs to change to improvepatent outcomes and

		experience.
4	Para 1.18	Radiotherapy UK has had regard to the guidance issued by the Charity Commission on public beneft. Radiotherapy UK is commited to making available to the public, informaton regarding radiotherapy treatment and its benefts, providing opportunites for radiotherapy professionals to share informaton as well as campaign for beter fundingfor radiotherapytreatment in the UK.

Additional information (optional)

You may choose to include further statements where relevant about:

	Contributon made by volunteers	Para 1.38	Volunteers are essental to our charity's success in delivering services. We depend on them to lead our organizaton through the Board, and to guide our eforts via the Ambassadors network, as well as patent and clinical engagementgroups.

Achievements and Performance

Achievements and Performance
	SORP reference
Summary of the main achievements of the charity, identfying the diference the charity’s work has made to the circumstances of its benefciaries and any wider benefts to society as a whole.	Para 1.20		In additon to the actvites noted above ,the charity has achieved the following this year for the beneft of patents, professionals, and the wider community: Advocacy and Policy  Development and delivery of landmark report from the APPG-Radiotherapy; ‘World-class Radiotherapy in the UK: Right Patent, Right Treatment, Right Time .’ The charity facilitated a UK-wide collaboraton to deliver a 10-year vision for radiotherapy that was launched in Parliament in February 2025.  As part of our 10-year vision work, the charity launched a patent survey to understand what patents and family members thought world-class radiotherapy would look like. We received 279 responses.  We atended two natonal conferences to amplify the World-class Radiotherapy report, presentng at the OPC in London and organising a ‘Big Hiter’ session at UKIO in London with patents and workforce leading an engaging session.  The charity had our frst abstract poster accepted for display at ESTRO 2024. Developed in partnership with the Global Coaliton for Radiotherapy, the poster highlighted the need for natonal and internatonal advocacy to improve access to radiotherapy. Poster can be viewedhere  Co-ordinated #CatchUpWithCancer day in parliament for World Cancer Day 2024. Over 20 cancer charites took part and over 60 MPs commited to working to improve how long cancer patents wait for treatment in the UK.  Actor, writer and comedian, Stephen Fry created a video supportng our #CatchUpWithCancer campaign, leading to an additonal 100,000 signatures on thechange.org petton in one day and bringingthe total amount of signatures to over

	600,000.
	In partnership with Global Coaliton for Radiotherapy
	organised ‘Integratng Radiotherapy into Cancer
	Plans’ event at London Global Cancer Week.
	Development, analysis and launch ofEquity of Access
	report found that 22% of the total populaton of the
	UK are further than the recommended 45 minutes
	from their closest radiotherapy service.
	Radiotherapy UK contnues to act as secretariate to
	the All-Party Parliamentary Group for Radiotherapy.
	At the end of this period, the APPG had 57
	members.
Patent Informaton Resources
	Radiotherapy UK was awardedPIF TICK accreditaton
	to become a ‘trusted informaton creator’ with the
	UK’s only assessed quality mark for print and online
	health and care informaton
	Coproducton of frstpatent‘virtual’video to help
	prepare patents for the experience of external beam
	radiotherapy (EBRT) for breast cancer.
	Coproducton and launch of new patent video series
	‘Understanding Gamma Knife radiotherapy.
	Eight group and individual meetngs for partcipants
	in our 2023 and 2024 Patent Engagement Groups
	Ten patent and eleven clinical reviewers supportng
	our patent informaton resource development
Workforce Engagement
	Five RTUK Talks webinars, with total registratons of
	843 and 1,291 views on YouTube. 2024 series
	launched with aim of fve talks sponsored by
	AstraZeneca.
	Workforce Ambassadors programme re-launched
	with 40 ambassadors in total engaged (16 from
	relaunch)
	Flash Workforce Survey 2023 launched. 803
	Responses (over 10% of the Radiotherapy
	workforce) to inform and support the advocacy work
	of the charity in amplifying the voice of the frontline
	workforce.
	Ofcial communicaton channel established with
	radiotherapy department managers via managers
	network chairperson.
Communicatons and Awareness
	The charity has a high media profle with regular
	press coverage on natonal news and major print
	publicatons. This year we also reached an
	internatonal audience following the news of the
	Princess of Wales’ diagnosis with our chair features
	in ABC News, PBS and the Washington Post. All
	coverage can be found here .
In line with our communicatons strategy, key social and
media channels have developed strongly over the course of
this year:
	LinkedIn: 75.6% followergrowth from 3,732 to

	6,554.
	Radiotherapy UK website: 40,000 new users.
	YouTube: 11,015 views, 492 watch hours, 83 new
	subscribers (176% increase)
	Radiotherapy Daily newsleter: Subscribers have
	grown steadily to 1,887 from 1,808. 1,498
	Instagram: grown from 2,402 followers to 2,538
	followers. (5.66% growth)
	Facebook: grown to 2,349 followers from 2,213.
	(6.15% growth)
	X: Analytcs now a paid-for service which we cannot
	justfy as a small charity. We are also reviewing
	whether we wish to contnue with this platorm.

Additional information (optional)

You may choose to include further statements where relevant about:

Achievements against objectves set	Para 1.41	N/A
Performance of fundraising actvites against objectves set	Para 1.41	N/A
Other		Corporate Partnerships The charity benefts from a number of corporate partnerships for example Varian (Siemens Healthineers) and Ergea co- sponsor the charity’s Daily News bulletn. All these partnerships are agreed on a vendor neutral basis.

Financial Review

Review of the charity’s fnancial positon at the end of the period	Para 1.21	The Charity’s total income for this fnancial year was £117,109 Total expenditure for this year was £162,760 leaving the charity with a year-end net defcit of £45,651 During 2023/2024 The Charity has managed to contnue its work within its limited budget by using its contacts and generous donatons in kind (resources) from Price Jones Ltd. With the current economic constraints and cost of living crisis this is a challenging tme for charity income generaton. However the charity are confdent that there are untapped avenues of funding available to the organisaton. To support accessing these, the charity will hire a part-tme fundraiser in FY24-25.
Statement explainingthepolicyfor	Para 1.22	RadiotherapyUK’spolicyis toprovide the charitywith

holding reserves statng why they are held		adequate fnancial stability and the means for it to meet its charitable objectves. Except for such funds as the Trustees consider prudent to maintain for the purposes of management and administraton of the charity for the foreseeable future, all unrestricted funds are used to the purpose of general objects of the charity. The adequacy of the reserves is reviewed annually.
Amount of reserves held	Para 1.22	£150,624 (excluding the related party loan mentoned below)
Details of fund materially in defcit	Para 1.24	The Charity has a long-term interest-free loan from related party Price Jones Ltd which is repayable at £2,500pa. The balance at June 2024 is £15,172
Explanaton of any uncertaintes about the charity contnuing as a goingconcern	Para 1.23	There are no current uncertaintes regarding the charity contnuing as a going concern.
Additional information (optional) You may choose to include further statements where relevant about:
The charity’s principal sources of funds (including any fundraising)	Para 1.47	The Charity’s main source of funds for this reportng period were: 1. Public Donatons via online giving and community events. 2. Corporate donatons from: BClear, Ergea, Brainlab, FlenHealth, Varian Siemens-Healthineers, Amethyst, AstraZeneca, Elekta, Price Jones, Accuray. 3. Radiotherapy4Life donaton for administratve and research analysis support.
Investment policy and objectves including any social investment policyadopted	Para 1.46	We do not currently hold enough reserves to warrant an investment policy.

A descripton of the principal risks facing the charity	Para 1.46	Current Challenges 1. Matching growth of charity to meet service development needs with fnancial constraints 2. Strained fnancial environment and COL crisis creates difcult circumstances for fundraising 3. Ensuring patents and benefciaries engaged with services and organisatonal development. 4. Developing appropriate governance structures in line with organisatonal growth. 5. Changing politcal environment 6. Contnuing crisis in delivery of cancer services exacerbated by workforce strikes, over-bureaucracy, limitng leadership and minimal investment.

	Other		Future initatves The following are considered to be priorites for the coming year: 1.Implement fnal year of current strategic plan and begin development of 2025 - 2028 strategy. 2.Recruit new Board members. 3.Development of detailed solutons following on from Radiotherapy Vision 2024 4.Launch of new online patent informaton hub 5.Recruitment of Relatonship Fundraiser Manager to develop income generaton avenues. 6.Expand workforce engagement initatves. 7.Contnue to campaign and advocate for increased access to high quality radiotherapy services across the UK

Structure, Governance and Management

Descripton of charity’s trusts:
Type of governing document (trust deed, royal charter)	Para 1.25	Consttuton
How is the charity consttuted? (e.g. unincorporated associaton, CIO)	Para 1.25	Associaton
Trustee selecton methods including details of any consttutonal provisions e.g. electon to post or name of any person or body enttled to appoint one or more trustees	Para 1.25	Original Trustees were nominated and elected by the ACORRN Scientfc Steering Commitee. New Trustees are nominated by the same process and are elected by consensus of the Board of Trustees of Radiotherapy UK.

Reference and Administrative details

Charityname	RadiotherapyUK(previouslyActon Radiotherapy)
Other name the charityuses	ACORRN
Registered charitynumber	1135902
Charity’s principal address	4 Abbotsbury House 139 Abbotsbury Road London W14 8EN

Names of the charity trustees who manage the charity

1 2 3 4 5 6	Trustee name	Ofce (if any)	Dates acted if not for whole year
	Professor Patricia Price	Chair
	Dr Christy Goldsmith	Secretary
	Ms Tanya Levine	Treasurer
	Dr Clive Harmer
	Professor Philip Mayles

Funds held as custodian trustees on behalf of others

Descripton of the assets held in this capacity	None
Name and objects of the charity on whose behalf the assets are held and how this falls within the custodian charity’s objects	None
Details of arrangements for safe custody and segregaton of such assets from the charity’s own assets	None

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of adviser Name Address

Name of chief executive or names of senior staff members (Optional information)

Sarah Quinlan – Charity Director

Exemptions from disclosure

Reason for non-disclosure of key personnel details Other optional information ~~OS So~~ Declarations The trustees declare that they have approved the trustees’ report above. Signed on behalf of the charity’s trustees Signature(s) Full name(s) Professor Pat Price ~~i Ee~~ Position (e.g. Secretary, Chair, etc Chair Date ~~———~~

Radiotherapy UK			1135902
Receipts andpayments accounts					CC16a
For the period from	23.06.2023	To	22.06.2024

Section A Receipts and payments

		Unrestricted funds		Restricted funds	Restricted	Endowment funds	Total funds	Last year
		to the nearest £	to the nearest	to the nearest £	to the nearest £	to the nearest £	to the nearest £	to the nearest £
A1 Receipts
Corporate donations		91,431		-	-	-	91,431	74,822
Community		23,208		-	-	-	23,208	21,752
Trusts & Foundations		2,470		-	-	-	2,470	32,000
		-		-	-	-	-	-
		-		-	-	-	-	-
		-		-	-	-	-	-
		-		-	-	-	-	-
		-		-	-	-	-	-
*Sub total*(Gross income for AR)	(Gross income for AR)	117,109 (Gross income for		-	-	-	117,109	128,574
- - - - - - - - - Sub total - - - - - Total receipts 117,109 - - 117,109 128,574 A2 Asset and investment sales, (see table). ~~—————=~~
A3 Payments
Advocacy& campaigning		11,537		-	-	-	11,537	2,387
Charityrunningcosts		5,626		-	-	-	5,626	2,960
Communications		8,318		-	-	-	8,318	6,909
Contractors		60,127		-	-	-	60,127	82,042
Incomegeneration		1,409		-	-	-	1,409	3,539
IT & development		5,734		-	-	-	5,734	4,335
Patient services		629		-	-	-	629	500
Professional fees		3,708		-	-	-	3,708	2,415
Promotional materials		823		-	-	-	823	42
Research & Data analytics		7,200		-	-	-	7,200	-
Salaries		53,617		-	-	-	53,617	3,836
Workforce services		255		-	-	-	255	391
Training& development		30		-	-	-	30	-
Loan repayment		2,500		-	-	-	2,500	2,500

**Sub total **		161,513		-	-	-	161,513	111,856
Computer equipment 1,247 - - 1,247 1,056 - - - - Sub total 1,247 - - 1,247 1,056 Total payments 162,760 - - 162,760 112,912 Net of receipts/(payments) - 45,651 - - - 45,651 15,661 A5 Transfers between funds - - - - - A6 Cash funds last year end 196,275 - - 196,275 180,614 Cash funds this year end 150,624 - - 150,624 196,275 A4 Asset and investment purchases, (see table) ~~——————~~ ~~===>>=>~~

Section B Statement of assets and liabilities at the end of the period

Categories B1 Cash funds B2 Other monetary assets B3 Investment assets B5 Liabilities B4 Assets retained for the charity’s own use Signed by one or two trustees on behalf of all the trustees	Details Bank Details Details Details Details Signature *Total cash funds* (agree balances with receipts and payments account(s)) Loan due to Professor Pat Price Limited	to nearest £ Unrestricted funds	to nearest £ Unrestricted funds
		150,624	-
		-	-
		-	-
		150,624	-
		OK to nearest £ Unrestricted funds
		-	-
		-	-
		-	-
		-	-
		-	-
		-	-
		Fund to which asset belongs
			-
			-
			-
			-
			-
		Fund to which asset belongs
			-
			-
			-
			-
			-
			-
			-
			-
			-
		Fund to which liability relates
			15,172
			-
			-
			-
			-

Trial Balance

Radiotherapy UK As at 22 June 2024 Cash Basis

Account Code	Account	Account Type
208	OnlinePlatforms: Amazon	Sales
218	Events: CharityAppeals(e.g. Xmas)	Sales
226	Corporate Donations	Sales
227	Community	Sales
234	Online Platforms: Just Giving	Sales
236	Events: Miles4Radiotherapy	Sales
240	Online Platforms(all)	Sales
242	Sales of Product Income	Sales
244	Services	Sales
246	Online Platforms: Stripe	Sales
248	Trusts &Foundations	Sales
400	Professional fees: Accounting	Overhead
402	IT&Development: AccountsManagement (Xero/QB)	Overhead
404	Advocacy& Campaigning (R4L)	Overhead
406	Professional fees: Bank Fees	Overhead
412	CharityRunning Costs: Entertaining	Overhead
414	Contractors: Comms Support	Overhead
418	Contractors:Communications Officer	Overhead
424	Contractors(all)	Overhead
425	Contractors(GCR)	Overhead
426	Communications: Coordination Platform	Overhead
430	Communications: DailyNews	Overhead
432	Contractors: Director	Overhead
434	CharityRunningCosts: Equipment	Overhead
436	Income Generation: Events	Overhead
438	Income Generation: Design work(non campaign)	Overhead
442	Professional fees: HR/Recruitment	Overhead
446	PatientServices	Overhead
448	Professional fees: Insurance	Overhead
452	Interest Payable	Overhead
454	Contractors: Internship	Overhead
456	IT & Development	Overhead
458	IT & Development: IT Support	Overhead
464	Professional fees: Licencing	Overhead
466	IT&Development: MarketingPlatform	Overhead
468	Professional fees: Memberships	Overhead
472	IT&Development: Monitoring &Evaluation Tools (SurveyMonkey)	Overhead
480	Research & Data Analysis	Overhead
481	Training& Development(RTUK team)	Overhead
490	Communications: Photography/Video production	Overhead
492	Income Generation: Platform Fees	Overhead
494	CharityRunning Costs: Postage	Overhead
495	CharityRunningCosts: Stationery	Overhead
500	Contractors: Project Manager	Overhead
504	Promotional Materials	Overhead
522	Salaries(inc.payeepension contributions)	Overhead
523	Salaries: Employerpensioncontributions	Overhead
526	IT & Development: Software	Overhead
530	CharityRunning Costs: Travel/Accommodation	Overhead
538	Workforce Services: Video Conference Tools	Overhead
540	IT & Development: Website Hosting	Overhead
542	IT&Development: WebsiteMaintenance	Overhead
544	Communications: Website Design Projects	Overhead
552	Workforce Services:Other	Overhead
806	Loan Repayments: Loan from PJ Ltd	Current Liability
600	Current	Bank
602	Equals Account	Bank
606	Savings	Bank
610/1	Debtors	Current Asset

820	VAT	Current Liability
902	OpeningBalance Equity	Equity
960	Retained Earnings	Equity
Total

Debit - Year to date Credit - Year to date Category 22Jun 2023	Debit - Year to date Credit - Year to date Category 22Jun 2023
0.00 Community (35.85)
0.00 Community 49.00
91,430.74 Corporate Donations (104,821.68)
5,014.25 Community 0.00
0.00 Community (8,099.30)
517.86 Community (12,584.87)
17,676.21 Community (682.97)
0.00 Community (247.75)
0.00 Community (51.49)
0.00 Community (44.30)
2,470.46 Trusts &Foundations (2,000.00)
1,991.24 Professional fees	936.00
271.40 IT& development	244.80
11,537.81 Advocacy& campaigning	2,386.76
84.60 Professional fees	90.00
0.00 Charityrunning costs	71.40
0.00 Contractors	900.00
0.00 Contractors	2,116.00
55,655.25 Contractors	2,700.00
680.00 Contractors	0.00
292.80 Communications	221.90
5,000.00 Communications	4,287.50
3,791.71 Contractors	46,667.20
1,247.21 Charityrunningcosts	1,056.29
1,408.55 Income generation	2,523.96
0.00 Incomegeneration	1,040.00
600.00 Professional fees	444.00
628.60 Patientservices	500.00
268.59 Professional fees 0.00 Interestpayable	259.60
	(0.04)
0.00 Contractors	4,383.46
22.40 IT & development	690.26
0.00 IT & development	374.37
625.56 Professional fees	650.60
1,030.34 IT& development	628.90
138.09 Professional fees	35.00
384.00 IT& development	384.00
7,200.00 Research & Data Analysis	0.00
30.00 Training& Development(RT 0.00
2,400.00 Communications 327.99
216.00 Charityrunningcosts 251.99
332.44 Charityrunning costs 89.29
43.52 Charityrunningcosts 0.00
0.00 Contractors 25,662.50
822.53 Promotional materials 42.00
51,434.64 Salaries 3,835.68
2,182.19 Salaries 0.00
4,013.94 IT & development 1,635.07
5,033.88 Charityrunning costs 2,460.57
235.08 Workforce services 225.50
0.00 IT & development 341.84
13.26 IT& development 35.99
625.00 Communications 1,700.00
19.48 Workforce services 150.00
2500 0.00 Loan (17,672.00)
46022.47 Bank 195,629.73
366.83 Bank 659.80
5.05 Bank 0.00
0.00 (106.30)

434.50		0.00
		(147,200.71)
		(13,141.69)
163,566.49	163,131.99	(0.00)

	Data
Category	Sum of Debit - Year to date Sum of Credit - Year to date
Advocacy & campaigning Charity running costs Communications Community Contractors Corporate Donations Income generation Interest payable IT & development Loan Patient services Professional fees Promotional materials Research & Data Analysis Salaries Training & Development (RTUK team) Trusts & Foundations Workforce services	11,537.81 6,873.05 8,317.80 23,208.32 60,126.96 91,430.74 1,408.55 0.00 5,735.34 2,500.00 0.00 628.60 3,708.08 822.53 7,200.00 53,616.83 30.00 2,470.46 254.56
Total Result	162,760.11 117,109.52

Client:	Prepared by:	Date:	Ref: A2.2
Year End:	Reviewed by:	Date:
File Number:

UNCORRECTED MISSTATEMENTS

Only those misstatements that are not regarded as clearly trivial should be recorded on this schedule. When considering whether a misstatement is material the auditor should consider size, nature and circumstances.

Final materiality:

Considered clearly trivial if below:

*Narrative*	*Extrapolated* *misstatements*	*Extrapolated* *misstatements*	*Actual misstatements*	*Actual misstatements*	*Profit and* *loss*	*Balance* *sheet*
	DR	CR	DR	CR






















Total of potential adjustments	-	-	-	-	-	-

Conclusion

The client has been asked to adjust for all misstatements noted above.
Where the client has not adjusted for misstatements drawn to their attention, the letter of representation explains the directors’ reasons for not adjusting as required by ISA 450.14.
None of the potential adjustments listed above are considered to be indicative of fraud.
None of the potential adjustments listed above individually or in total indicate that the overall strategy and audit plan need to be revised.

Croner-i Audit - October 2018

Page 8 of 9

B7 Page9of9 Croner-i Audit - October 2018

Independent Examiner's Report to the Trustees of Radiotherapy UK

I report to the trustees on my examination of the accounts of Radiotherapy UK for the year ended 22 June 2024.

Responsibilities and basis of report

As the charity trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011. (‘the Act’).

I report in respect of my examination of the Trust’s accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner’s statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

Accounting records were not kept in respect of the Trust as required by section 130 of the Act; or
The accounts do not accord with those records.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report to enable a proper understanding of the accounts to be reached.

Susan Redmond FCA DJH Limited Chartered Accountants St George's House 56 Peter Street Manchester M2 3NQ

20[th] December 2024

RADIOTHERAPY UK YEAR ENDED 22 JUNE 2024 NOTES TO ACCOUNTS

Interest-free loan

The charity received an interest-free loan from Price Jones Limited, a company in which one of the trustees Professor Patricia Price is a director and shareholder. The loan currently stands at £15,172 and is repayable at £2,500 per annum beginning 1 July 2017.

Related party transactions

During the year there was a further £4,676 (2023: £2,462) paid to Professor Pat Price Limited. These were for general administrative costs, and costs relating to the All Party Parliamentary Group for Radiotherapy. All transactions were considered to be at arm’s length.

During the year donations of £40,000 (2023:£44,083) were received from Radiotherapy4Life Limited, a company in which one of the trustees Patricia Price is a director and shareholder. Donations of £5,000 were received from Professor Pat Price Limited, a company in which Patricia Price is also a director.